Tanovea™-CA1 (rabacfosadine) is a novel antineoplastic agent that is conditionally approved for use in dogs with lymphoma. Rabacfosadine is a guanine nucleotide prodrug. The cytotoxicity is mediated by selective inhibition of DNA polymerases in replicating lymphoid tissue.


  • 1 mg/kg
  • 30-minute intravenous infusion, once every 3 weeks, for up to 5 doses

Dosage form and Storage

  • Single-use vials with 16.4mg of lyophilized rabacfosadine (white crystalline powder)
  • Reconstituted concentration is 8.2 mg/mL
  • Unopened vials are stored in the refrigerator and do not need to be protected from light


  • Pulmonary fibrosis: Do not use in West Highland White Terriers or any dog with a history of or risk for pulmonary fibrosis or chronic bronchitis
  • Pregnancy, lactation, dogs intended for breeding



Full-Text Articles

  1. Thamm DH, Vail DM, Post GS, et al. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naıve Canine Multicentric Lymphoma. J Vet Intern Med 2017;31:872–878. Download article
  2. Lawrence J, Vanderhoek M, Barbee D, et al. Use of 3′-deoxy-3′-18Ffluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin’s lymphoma. Vet Radiol Ultrasound. 2009;50(6):660-8. Download article
  3. Thamm DH, Vail DM, Kurzman ID, et al. GS-9219/VDC-1101 – a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma. BMC Veterinary Research2014,10:30. Download article
  4. Reiser H, Wang J, Chong L, et al. GS-9219 – A novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin’s lymphoma. Clin Cancer Res 2008;14(9):2824-2832. Download article


  1. Thamm DH, Morges MA, Clifford CA, et al. Rabacdosadine and prednisone: Efficacy of a Q21 day administration schedule in canine lymphoma. From the Proceedings of the 2015 ACVIM Annual Forum (VC-003). Download abstract
  2. Vickery KR, Clifford CA, Burgess KE, et al. Rabacfosadine for relapsed canine B cell lymphoma: Efficacy and adverse event profiles of two different doses. From the Proceedings of the 2016 VCS Annual Conference, Oral Abstract Presentation (VC-008). Download abstract

Additional resources

Last updated: 2017-08-15